TrustArc Webinar - Stay Ahead of US State Data Privacy Law Developments
Inappropriate Prescribing Of Antimicrobials
1. Inappropriate combinations of antimicrobial agents Munzur Morshed, Pharm D. candidate 2011 Arnold & Marie Schwartz College of Pharmacy and Health Sciences North Shore- Long Island Jewish Health System Infectious Diseases-Advanced Pharmacy Practice
72. Fluoroquinolone plus Macrolides cont… Avelox plus Erythromycin or Avelox plus Azithromycin Combination of a fluoroquinolone and a macrolide Avelox SOA- Pseudomonas, Strep. , Staph. Enterobacter Erythro./Azithro. SOA- Strep. , Moraxella Catarrahalis, Chlamydia pneumonia. Avoid use Major Drug Interactions- additive effect Causes QT interval prolongation-Life threatening ventricular arrhythmias
99. Arnold SR, Straus SE. "Interventions to improve antibiotic prescribing practices in ambulatory care". Cochrane Database Syst Rev,2005 (4)-Accessed on may 25,2010.
100. Tausk F, Evans ME, Patterson LS, et al. Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother1985; 28(1):41—45. Accessed on May 25, 2010. Accessed on may 25,2010
101. Boghossian J, Caputo W,, Dana A, Gray S, Harkless L, Pollak R,, Wu D. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surgical Infections. 2005: 6(1): 27-40. Accessed on may 25,2010
102. Arranz R, de La Cámara R, Figuera A,, Font P, Leyra F, Pajuelo F, Rivero N. Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996). Med Clin (Barc). 2001 May 5;116(16):610-1. Accessed on may 25,2010
103. Alvarez-Lerma F, Barcenilla F., Insausti-Ordeñana J, Jordá-Marcos R,, Maraví-Poma E, Martínez-Pellús A, Nava J,, Palomar M, Barcenilla F, Torres-Martí A,. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med. 2001 Mar;27(3):493-502. Accessed on may 25,2010
104. Brun-Buisson C,Brière S, Petit C. Sollet JP, Schweich H Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis. 1998 Feb;26(2):346-54. Accessed on may 25,2010
105. Andrien F, Anniko M, Baudrihaye M, Bow E, Burman LA, Louie T, Norrby SR, Vandercam B. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Perit Dial Int. 2004 Sep-Oct;24(5):440-6. Accessed on may 25,2010
106. ,Chow KM., Leung CB, , Lui SF, Li PK. , Szeto CC, Wang AY, Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial. Perit Dial Int. 2004 Sep-Oct;24(5):440-6. Accessed on may 25,2010